Title (en)

FORMULATION ARRAYS AND USE THEREOF

Title (de)

FORMULIERUNGSMATRIZEN UND DEREN VERWENDUNG

Title (fr)

JEU ORDONNE D'ECHANTILLONS DE PREPARATIONS ET UTILISATION

Publication

EP 1171231 A1 20020116 (EN)

Application

EP 00919961 A 20000331

Priority

- US 0008589 W 20000331
- US 12775599 P 19990405
- US 14601999 P 19990728

Abstract (en)

[origin: WO0059627A1] Methods have been developed which use high throughput combinatorial formulation technologies, preferably in combination with nanotechnology and microarrays, to improve one or more properties of materials used as components of, or in the manufacture or use of, health care products, consumer products, agricultural products, nutraceutical products, veterinary products, products for use in manufacturing or processing industries, military applications, and research reagents. In a preferred application, the bioavailability and pharmacokinetics of the drugs, especially small molecule pharmaceuticals, are optimized by making many new formulations and selecting those formulations based on one or more physical or chemical properties such as solubility in an aqueous solution, without compromising selectivity or potency. Systems employing these technologies have been designed to rapidly, systematically and cheap identify optimal compositions for a desired purpose. In one preferred embodiment, new formulations are prepared and tested for bioequivalence to a formulation that is approved or commercially available. In another embodiment, the formulations are initially optimized in vitro for their pharmacokinetics, such as absorption through the gut (for an oral preparation), skin (for transdermal application), or mucosa (for nasal, buccal, vaginal or rectal formulation), solubility, degradation or clearance by uptake into the reticuloendothelial system ("RES"), metabolism or elimination, then tested in vivo.

IPC 1-7

B01J 19/00; A61K 47/00; G01N 33/50

IPC 8 full level

A61K 47/00 (2006.01); **A61K 47/12** (2006.01); **A61K 47/14** (2006.01); **A61K 47/20** (2006.01); **A61K 47/24** (2006.01); **A61K 47/32** (2006.01); **A61K 47/34** (2006.01); **A61K 47/36** (2006.01); **A61K 47/40** (2006.01); **B01J 19/00** (2006.01); **G01N 33/15** (2006.01); **G01N 33/50** (2006.01); **G01N 33/53** (2006.01); **G01N 37/00** (2006.01); C07B 61/00 (2006.01); C40B 40/18 (2006.01); C40B 60/14 (2006.01)

CPC (source: EP KR)

A61K 47/00 (2013.01 - EP); **B01J 19/0046** (2013.01 - EP); **G01N 33/50** (2013.01 - KR); B01J 2219/00315 (2013.01 - EP); B01J 2219/00317 (2013.01 - EP); B01J 2219/00351 (2013.01 - EP); B01J 2219/00378 (2013.01 - EP); B01J 2219/00659 (2013.01 - EP); B01J 2219/00689 (2013.01 - EP); B01J 2219/00702 (2013.01 - EP); B01J 2219/0072 (2013.01 - EP); B01J 2219/00745 (2013.01 - EP); B01J 2219/00756 (2013.01 - EP); C40B 40/18 (2013.01 - EP); C40B 60/14 (2013.01 - EP)

Citation (search report)

See references of WO 0059627A1

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

WO 0059627 A1 20001012; AU 4056600 A 20001023; AU 775665 B2 20040812; BR 0009588 A 20011226; CA 2365851 A1 20001012; CZ 20013606 A3 20020417; EP 1171231 A1 20020116; HK 1045274 A1 20021122; IL 145715 A0 20020725; JP 2002541442 A 20021203; KR 20020021783 A 20020322; MX PA01009971 A 20020730; NZ 514592 A 20040227; SK 14062001 A3 20021203

DOCDB simple family (application)

US 0008589 W 20000331; AU 4056600 A 20000331; BR 0009588 A 20000331; CA 2365851 A 20000331; CZ 20013606 A 20000331; EP 00919961 A 20000331; HK 02105133 A 20020710; IL 14571500 A 20000331; JP 2000609181 A 20000331; KR 20017012730 A 20011005; MX PA01009971 A 20000331; NZ 51459200 A 20000331; SK 14062001 A 20000331